

# Meredith M Regan, Scd

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3558269/meredith-m-regan-scd-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

198  
papers

16,812  
citations

62  
h-index

128  
g-index

207  
ext. papers

19,725  
ext. citations

7.3  
avg, IF

5.87  
L-index

#	Paper	IF	Citations
198	Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy.. <i>Oncologist</i> , <b>2022</b> , 27, 266-271	5.7	0
197	Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?. <i>Breast</i> , <b>2022</b> ,	3.6	
196	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.. <i>European Journal of Cancer</i> , <b>2022</b> , 164, 39-51	7.5	1
195	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	4
194	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 <b>2021</b> , 9,		2
193	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1485-1505	2.2	102
192	Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2021</b> , 44, 449-455	2.7	0
191	Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 185, 697-707	4.4	3
190	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 504-512	12.9	3
189	Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial. <i>Cancer</i> , <b>2021</b> , 127, 700-708	6.4	0
188	Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 87, 673-679	3.5	5
187	A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5472-5481	12.9	0
186	Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial. <i>BMJ Open</i> , <b>2021</b> , 11, e045239	3	1
185	Estimation of historical control rate for a single arm de-escalation study - Application to the POSITIVE trial. <i>Breast</i> , <b>2020</b> , 53, 1-7	3.6	6
184	DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. <i>Npj Breast Cancer</i> , <b>2020</b> , 6, 3	7.8	9
183	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1346-1366	2.2	249
182	Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2020</b> , 144, 545-563	5	82

181	Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. <i>Immunotherapy</i> , <b>2020</b> , 12, 37-51	3.8	5
180	Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 181, 347-359	4.4	7
179	Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4120-4129	2.2	7
178	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6122-6131	12.9	4
177	Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1293-1303	2.2	45
176	Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute® Inflammatory Breast Cancer Program experience. <i>Breast Journal</i> , <b>2020</b> , 26, 384-390	1.2	4
175	Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3350-3358	2.2	23
174	Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz051	4.6	1
173	Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 176, 557-568	4.4	5
172	Reply to K.-D. Yu et al. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1516-1517	2.2	
171	A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz002	4.6	18
170	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 105-114	2.2	38
169	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 959-967	8.7	3
168	Prevalence of germline variants in inflammatory breast cancer. <i>Cancer</i> , <b>2019</b> , 125, 2194-2202	6.4	10
167	Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 862-866	2.2	14
166	Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 30	8.3	37
165	Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer. <i>Urology</i> , <b>2019</b> , 127, 53-60	1.6	4
164	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. <i>Lancet Oncology</i> , <b>2019</b> , 20, 371-382	21.7	200

163	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz049	4.6	4
162	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz050	4.6	6
161	Sensitivity of treatment-free survival (TFS), a novel outcome, to subgroup analyses of patients (pts) with advanced melanoma (MEL) treated with immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 9550-9550	2.2	
160	Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 538-538	2.2	
159	Clinical and economic outcomes associated with sequential treatment in patients with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4566-4566	2.2	
158	Risk stratification according to stage and pathology. <i>Breast</i> , <b>2019</b> , 48 Suppl 1, S23-S25	3.6	1
157	Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. <i>Oncologist</i> , <b>2019</b> , 24, 165-171	5.7	13
156	Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. <i>Quality of Life Research</i> , <b>2019</b> , 28, 109-119	3.7	8
155	Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. <i>Immunotherapy</i> , <b>2019</b> , 11, 283-295	3.8	13
154	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 170, 351-360	4.4	5
153	Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al. <i>Quality of Life Research</i> , <b>2018</b> , 27, 149-152	3.7	3
152	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 122-137	59.2	270
151	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1335-1343	13.4	24
150	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 127-138	21.7	62
149	Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1941-1948	2.2	73
148	National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3259-3268	2.2	10
147	Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1073-1079	2.2	62
146	Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. <i>Immunotherapy</i> , <b>2018</b> , 10, 1241-1252	3.8	15

145	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1385-1393	21.7	195
144	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1434-1441	8.7	17
143	Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP. <i>Practical Radiation Oncology</i> , <b>2018</b> , 8, 445-451	2.8	1
142	HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. <i>European Journal of Cancer</i> , <b>2017</b> , 79, 129-138	7.5	11
141	Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1085-1093	13.4	88
140	The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 2563-2569	3.1	13
139	External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 98, 304-317	4	17
138	Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity. <i>American Journal of Epidemiology</i> , <b>2017</b> , 185, 75-85	3.8	27
137	Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3113-3122	2.2	68
136	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3097-3104	2.2	215
135	Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1179-1188	2.2	71
134	Reply to L. Moscetti. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1628	2.2	10
133	Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2017</b> , 23, 63-67	2.2	8
132	Trial designs and results supporting treatment de-escalation and escalation. <i>Breast</i> , <b>2017</b> , 34 Suppl 1, S10-S12	3.6	4
131	Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 398-406	3.1	18
130	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. <i>JCO Precision Oncology</i> , <b>2017</b> , 1,	3.6	7
129	Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 110	8.3	15
128	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3400-8	2.2	56

127	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, e299-305	3.3	9
126	The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. <i>JAMA Oncology</i> , <b>2016</b> , 2, 217-24	13.4	19
125	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 158, 323-31	4.4	73
124	Reply to F. Tomao et al. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4189-4190	2.2	
123	Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1601-10	2.2	75
122	Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2221-31	2.2	112
121	Adjuvant ovarian function suppression and cognitive function in women with breast cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 956-64	8.7	30
120	Are SOFT and TEXT results practice changing and how?. <i>Breast</i> , <b>2016</b> , 27, 122-5	3.6	10
119	Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2772-9	2.2	91
118	Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. <i>Lancet Oncology</i> , <b>2015</b> , 16, 848-58	21.7	106
117	Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 151, 225-32	4.4	19
116	The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 561-8	12.9	114
115	CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 151, 373-84	4.4	24
114	Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 2483-91	3.1	19
113	Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. <i>Molecular Oncology</i> , <b>2015</b> , 9, 1868-76	7.9	17
112	Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 154, 275-86	4.4	30
111	Predicting benefit of endocrine therapy for early breast cancer. <i>Breast</i> , <b>2015</b> , 24 Suppl 2, S129-31	3.6	2
110	ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 154, 543-55	4.4	11

109	Adjuvant ovarian suppression in premenopausal breast cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 436-46	59.2	462
108	Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 107-18	59.2	500
107	Exemestane with ovarian suppression in premenopausal breast cancer. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1358-9	59.2	15
106	Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. <i>Cancer</i> , <b>2014</b> , 120, 1076-82	6.4	65
105	Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. <i>Journal of Urology</i> , <b>2014</b> , 191, 638-45	2.5	43
104	Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. <i>Lancet Oncology</i> , <b>2013</b> , 14, 297-305	21.7	775
103	Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. <i>Breast</i> , <b>2013</b> , 22, 1094-100	3.6	63
102	Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 566-71	2.8	160
101	Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1332-4	9.7	31
100	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. <i>Lancet Oncology</i> , <b>2013</b> , 14, 141-8	21.7	598
99	Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. <i>Breast</i> , <b>2013</b> , 22, 130-137	3.6	38
98	Dramatic and prolonged PSA response after retreatment with a PSA vaccine. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 362-4	3.3	3
97	Challenges of guarantee-time bias. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2963-9	2.2	271
96	TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. <i>Future Oncology</i> , <b>2013</b> , 9, 1477-87	3.6	9
95	SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 6478-87	5.4	50
94	Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response. <i>PLoS ONE</i> , <b>2013</b> , 8, e64225	3.7	12
93	The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 131, 295-306	4.4	8
92	CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 441-51	9.7	273

91	Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. <i>Breast Cancer Research</i> , <b>2012</b> , 14, R143	8.3	43
90	A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer. <i>Breast</i> , <b>2012</b> , 21, 621-8	3.6	2
89	The effect of a controlled 8-week metabolic ward based lysine supplementation on muscle function, insulin sensitivity and leucine kinetics in young men. <i>Clinical Nutrition</i> , <b>2012</b> , 31, 903-10	5.9	8
88	Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial. <i>Cancer</i> , <b>2012</b> , 118, 2651-8	6.4	16
87	Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 6686-91	11.5	42
86	Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3967-75	2.2	83
85	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 81 years median follow-up. <i>Lancet Oncology</i> , <b>2011</b> , 12, 1101-8	21.7	298
84	Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. <i>Cancer Prevention Research</i> , <b>2011</b> , 4, 719-28	3.2	38
83	Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. <i>Breast Cancer Research</i> , <b>2011</b> , 13, 209	8.3	53
82	Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. <i>BJU International</i> , <b>2011</b> , 107, 126-34	5.6	32
81	Secondary hormonal therapy in men with castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2011</b> , 9, 95-103	3.3	13
80	Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients. <i>Cancer</i> , <b>2011</b> , 117, 517-25	6.4	29
79	Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1117-24	2.2	115
78	Prediction of erectile function following treatment for prostate cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 306, 1205-14	27.4	213
77	Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. <i>BJU International</i> , <b>2010</b> , 106, 772-8	5.6	73
76	Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. <i>Annals of Oncology</i> , <b>2010</b> , 21, 312-318	10.3	32
75	Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2966-73	2.2	107
74	8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 9742-6	11.5	295

73	Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. <i>PLoS Genetics</i> , <b>2010</b> , 6, e1001204	6	70
72	Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article. <i>Journal of Neurosurgery: Spine</i> , <b>2010</b> , 13, 789-94	2.8	30
71	A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial. <i>Fertility and Sterility</i> , <b>2010</b> , 94, 888-99	4.8	170
70	Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. <i>BJU International</i> , <b>2010</b> , 105, 1392-6	5.6	20
69	Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 121, 211-8	4.4	31
68	Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7099-105	12.9	59
67	Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 766-76	59.2	387
66	Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4706-11	12.9	181
65	Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5794-9	2.2	1390
64	Evaluation of the 8q24 prostate cancer risk locus and MYC expression. <i>Cancer Research</i> , <b>2009</b> , 69, 5568-74	4.1	102
63	Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer. <i>Journal of the American College of Surgeons</i> , <b>2009</b> , 208, 202-9	4.4	43
62	Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. <i>Cancer</i> , <b>2009</b> , 115, 981-7	6.4	87
61	The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. <i>Nature Genetics</i> , <b>2009</b> , 41, 882-4	36.3	550
60	Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. <i>Cell</i> , <b>2009</b> , 138, 245-56	56.2	691
59	Absence of relationship between steroid hormone levels and prostate cancer tumor grade. <i>Urology</i> , <b>2009</b> , 73, 356-61; discussion 361-2	1.6	28
58	Statistical issues and challenges. <i>Cancer Treatment and Research</i> , <b>2009</b> , 151, 77-90	3.5	
57	Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. <i>BJU International</i> , <b>2008</b> , 101, 308-12	5.6	37
56	Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. <i>Lancet Oncology, The</i> , <b>2008</b> , 9, 23-8	21.7	131

55	Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 207-12	9.7	183
54	Physicians' experiences with BRCA1/2 testing in community settings. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5789-96	2.2	32
53	Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1404-10	2.2	84
52	Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5569-75	2.2	262
51	Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 842-7	2.2	86
50	Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1231-1241	10.3	43
49	Relationship between serum adiponectin and prostate cancer grade. <i>Prostate</i> , <b>2008</b> , 68, 1592-8	4.2	41
48	Using clinical trial data to tailor adjuvant treatments for individual patients. <i>Breast</i> , <b>2007</b> , 16 Suppl 2, S98-104	3.6	4
47	Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3846-52	2.2	340
46	Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2007</b> , 13, 125-9	2.2	12
45	Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. <i>Urology</i> , <b>2007</b> , 70, 527-31	1.6	17
44	Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials. <i>Clinical Genitourinary Cancer</i> , <b>2006</b> , 5, 114-9	3.3	17
43	Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. <i>Journal of the National Cancer Institute</i> , <b>2006</b> , 98, 1571-81	9.7	129
42	Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5408-13	2.2	22
41	The daily phenylalanine requirement of healthy Indian adults. <i>American Journal of Clinical Nutrition</i> , <b>2006</b> , 83, 1331-6	7	16
40	Branched-chain amino acid requirements in healthy adult human subjects. <i>Journal of Nutrition</i> , <b>2006</b> , 136, 256S-63S	4.1	20
39	Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. <i>BJU International</i> , <b>2005</b> , 96, 783-6	5.6	21
38	Predicting response to systemic treatments: learning from the past to plan for the future. <i>Breast</i> , <b>2005</b> , 14, 582-93	3.6	23

37	The daily valine requirement of healthy adult Indians determined by the 24-h indicator amino acid balance approach. <i>American Journal of Clinical Nutrition</i> , <b>2005</b> , 82, 373-379	7	10
36	Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 133-41 <sup>2.2</sup>		624
35	Effect of cystine on the methionine requirement of healthy Indian men determined by using the 24-h indicator amino acid balance approach. <i>American Journal of Clinical Nutrition</i> , <b>2004</b> , 80, 1526-35	7	18
34	Daily requirement for total sulfur amino acids of chronically undernourished Indian men. <i>American Journal of Clinical Nutrition</i> , <b>2004</b> , 80, 95-100	7	13
33	Association of cystic fibrosis with abnormalities in fatty acid metabolism. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 560-9	59.2	318
32	Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered. <i>Vaccine Journal</i> , <b>2004</b> , 11, 819-24		69
31	Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 4951-7	2.2	119
30	Survey of breast-feeding practices and outcomes in the cystic fibrosis population. <i>Pediatric Pulmonology</i> , <b>2004</b> , 37, 362-7	3.5	20
29	Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 678-83	15.1	816
28	Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. <i>Urology</i> , <b>2004</b> , 63, 327-32	1.6	25
27	Initiation of the gonadotropin-releasing hormone antagonist ganirelix for in vitro fertilization cycles in which the lead follicle is >14 mm. <i>Fertility and Sterility</i> , <b>2004</b> , 81, 714-5	4.8	6
26	Inotropes improve right heart function in patients undergoing aortic valve replacement for aortic stenosis. <i>Anesthesia and Analgesia</i> , <b>2004</b> , 98, 891-902	3.9	22
25	Lysine requirements of chronically undernourished adult Indian men, measured by a 24-h indicator amino acid oxidation and balance technique. <i>American Journal of Clinical Nutrition</i> , <b>2003</b> , 77, 101-8	7	48
24	Effects of normal meals rich in carbohydrates or proteins on plasma tryptophan and tyrosine ratios. <i>American Journal of Clinical Nutrition</i> , <b>2003</b> , 77, 128-32	7	137
23	Daily methionine requirements of healthy Indian men, measured by a 24-h indicator amino acid oxidation and balance technique. <i>American Journal of Clinical Nutrition</i> , <b>2003</b> , 77, 1198-205	7	40
22	Leucine requirement and splanchnic uptake of leucine in chronically undernourished adult Indian subjects. <i>American Journal of Clinical Nutrition</i> , <b>2003</b> , 77, 861-7	7	18
21	Intestinal parasites increase the dietary lysine requirement in chronically undernourished Indian men. <i>American Journal of Clinical Nutrition</i> , <b>2003</b> , 78, 1145-51	7	33
20	Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. <i>Human Genetics</i> , <b>2003</b> , 113, 286-92	6.3	81

19	Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 3282-7	12.9	39
18	Threonine requirements of healthy Indian men, measured by a 24-h indicator amino acid oxidation and balance technique. <i>American Journal of Clinical Nutrition</i> , <b>2002</b> , 76, 789-97	7	32
17	Intravenously infused <sup>13</sup> C-leucine is retained in fasting healthy adult men. <i>Journal of Nutrition</i> , <b>2002</b> , 132, 1906-8	4.1	5
16	Lysine requirements of healthy adult Indian subjects receiving long-term feeding, measured with a 24-h indicator amino acid oxidation and balance technique. <i>American Journal of Clinical Nutrition</i> , <b>2002</b> , 76, 404-12	7	45
15	Threonine requirement of healthy adults, derived with a 24-h indicator amino acid balance technique. <i>American Journal of Clinical Nutrition</i> , <b>2002</b> , 75, 698-704	7	18
14	Precardiopulmonary bypass right ventricular function is associated with poor outcome after coronary artery bypass grafting in patients with severe left ventricular systolic dysfunction. <i>Anesthesia and Analgesia</i> , <b>2002</b> , 95, 1507-18, table of contents	3.9	153
13	Two latent variable risk assessment approaches for mixed continuous and discrete outcomes from developmental toxicity data. <i>Journal of Agricultural, Biological, and Environmental Statistics</i> , <b>2001</b> , 6, 340-355	1.0	21
12	Melatonin treatment for age-related insomnia. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 4727-30	5.6	188
11	Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics. <i>Journal of Virology</i> , <b>2001</b> , 75, 11234-8	6.6	48
10	Gender bias in the disposition of frozen embryos. <i>Fertility and Sterility</i> , <b>2001</b> , 76, 1181-4	4.8	9
9	Why do older women discontinue hormone replacement therapy?. <i>Journal of Women's Health and Gender-Based Medicine</i> , <b>2001</b> , 10, 343-50		24
8	Daily requirement for and splanchnic uptake of leucine in healthy adult Indians. <i>American Journal of Clinical Nutrition</i> , <b>2001</b> , 74, 747-55	7	31
7	Lysine requirements of healthy adult Indian subjects, measured by an indicator amino acid balance technique. <i>American Journal of Clinical Nutrition</i> , <b>2001</b> , 73, 900-7	7	55
6	Regression models and risk estimation for mixed discrete and continuous outcomes in developmental toxicology. <i>Risk Analysis</i> , <b>2000</b> , 20, 363-76	3.9	14
5	Cysteine kinetics and oxidation at different intakes of methionine and cystine in young adults. <i>American Journal of Clinical Nutrition</i> , <b>2000</b> , 71, 491-9	7	53
4	Incorporation of urea and ammonia nitrogen into ileal and fecal microbial proteins and plasma free amino acids in normal men and ileostomates. <i>American Journal of Clinical Nutrition</i> , <b>1999</b> , 70, 1046-58	7	81
3	Likelihood models for clustered binary and continuous outcomes: application to developmental toxicology. <i>Biometrics</i> , <b>1999</b> , 55, 760-8	1.8	57
2	Echocardiographic predictors of left ventricular outflow tract obstruction and systolic anterior motion of the mitral valve after mitral valve reconstruction for myxomatous valve disease. <i>Journal of the American College of Cardiology</i> , <b>1999</b> , 34, 2096-104	15.1	192

- 1 Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. *Annals of Pharmacotherapy*, **1995**, 29, 459-64 2.9 33